Profile data is unavailable for this security.
About the company
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.51m
- Incorporated2021
- Employees--
- LocationMarvel Biosciences CorpSuite 420, 505 8th Avenue S.W.CALGARY T2P 1G2CanadaCAN
- Phone+1 (403) 770-2469
- Websitehttps://marvelbiotechnology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| StageZero Life Sciences Ltd | 4.10m | -17.15m | 4.92m | 40.00 | -- | -- | -- | 1.20 | -0.1617 | -0.1617 | 0.0378 | -0.1005 | 0.6717 | 22.87 | 48.05 | 102,417.90 | -281.22 | -135.76 | -- | -- | 0.3457 | -2.74 | -418.64 | -246.92 | 0.0329 | -14.74 | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Principal Technologies Inc | 581.16k | -1.52m | 4.93m | -- | -- | 6.07 | -- | 8.48 | -0.0657 | -0.0657 | 0.0257 | 0.0247 | 0.577 | -- | 3.71 | -- | -147.50 | -- | -286.94 | -- | 42.98 | -- | -255.65 | -- | -- | -59.80 | 0.0757 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
| Titan Medical Inc | 24.13m | 9.51m | 5.70m | 4.00 | 0.8559 | 0.8708 | 0.5837 | 0.2363 | 0.0584 | 0.0584 | 0.1965 | 0.0574 | 2.22 | -- | -- | 6,031,907.00 | 87.56 | -113.26 | 365.95 | -793.56 | -- | -- | 39.43 | -201.89 | -- | -- | 0.2166 | -- | -- | -- | 116.34 | -- | -12.72 | -- |
| Marvel Biosciences Corp | 0.00 | -2.51m | 5.77m | -- | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.0617 | 0.00 | -- | -- | -- | -372.25 | -- | -- | -- | -- | -- | -- | -- | -- | -26.43 | -- | -- | -- | -- | 10.29 | -- | -- | -- |
| Good Shroom Co Inc | 4.26m | -35.66k | 6.09m | -- | -- | 9.88 | -- | 1.43 | -0.0007 | -0.0007 | 0.0852 | 0.0121 | 2.57 | 6.04 | 7.33 | -- | -2.15 | -- | -5.42 | -- | 26.23 | -- | -0.8368 | -- | 1.01 | -4.80 | 0.0971 | -- | 160.30 | -- | 72.24 | -- | -- | -- |
| Rakovina Therapeutics Inc | 0.00 | -2.61m | 6.31m | -- | -- | 1.72 | -- | -- | -0.0374 | -0.0374 | 0.00 | 0.0522 | 0.00 | -- | -- | -- | -46.38 | -- | -47.48 | -- | -- | -- | -- | -- | -- | -28.52 | 0.267 | -- | -- | -- | 6.39 | -- | -- | -- |
